Back to top

Tale of the Tape

Zacks Equity Research

Is This the Top for Halozyme Therapeutics, Inc. (HALO)

HALO

Trades from $3
Read Full ArticleHide Full Article
Halozyme Therapeutics, Inc. (HALO - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because HALO is now in overbought territory with an RSI value of 73.9. Furthermore, estimates for the Halozyme Therapeutics, Inc. have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.



In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Halozyme Therapeutics, Inc. (HALO) - free report >>